🇺🇸 FDA
Patent

US 12377115

Combination immunotherapies for treatment of cancer

granted A61KA61K2039/5254A61K2039/55588

Quick answer

US patent 12377115 (Combination immunotherapies for treatment of cancer) held by PrimeVax Immuno-Oncology expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PrimeVax Immuno-Oncology
Grant date
Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K2039/5254, A61K2039/55588, A61K2039/585, A61K2039/70